I-Mab, a Rockville-based global biotech company that recently divested from its Chinese parent company, Tuesday announced it has filed its annual report on Form 20-F for the year ended Dec. 31, 2023, with the U.S. Securities and Exchange Commission.
I-MAB focuses exclusively on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer,
The annual report is available on the company’s investor relations website at ir.i-mabbiopharma.com and on the SEC’s website at www.sec.gov. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request.